Get all your AEON Biopharma news in one place.

Apr 05, 2021

AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia

-Topline data expected in early-2022- Newport Beach, Calif., April 5, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary…

Oct 08, 2019

AEON Biopharma Appoints Chris Carr as Chief Financial Officer and Scott Akamine as General Counsel

Biopharma Firm Continues to Build Industry Leading Management Team; Poised for Next Phase of Growth in Therapeutic Toxin Market NEWPORT BEACH, Calif., October 1, 2019 – AEON Biopharma, an emerging…

Sep 16, 2019

AEON Biopharma Appoints BOTOX® Therapeutic Head as President and Chief Executive Officer

Dynamic Industry Veteran Led Multi-Billion Dollar Therapeutic Neurotoxin Portfolio NEWPORT BEACH, Calif., May 13, 2019 /PRNewswire/ -- ALPHAEON Corporation announced today that its Board of Directors has named Marc Forth as President and Chief Executive…